Description:

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer Inclusion Criteria: - Diagnosis of prostate cancer. - Rising PSA while on hormonal therapy or following surgical castration. - Documented evidence of metastatic disease. Exclusion Criteria: - Have received cytotoxic chemotherapy. - Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months

Keywords:
Versions (1) ▾
  1. 12/9/13
Uploaded on:

December 9, 2013

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility DRKS00009647 NCT00036543 Prostate Cancer

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion criteria
Diagnosis of prostate cancer
Rising PSA while on hormonal therapy or following surgical castration
Documented evidence of metastatic disease
Exclusion criteria
Have received cytotoxic chemotherapy
Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months
Medical Concepts